


(VI b)

18. The antisense oligomer compound of any one of claims 1-17, wherein the antisense oligomer compound is a pharmaceutically acceptable salt of 0.6 HCl.

19. A pharmaceutical composition, comprising an antisense oligomer compound according to any one of claims 1-18 and a pharmaceutically acceptable carrier.

20. Use of an antisense oligomer compound according to any one of claims 1-18 or the pharmaceutical composition of claim 19 in the manufacture of a medicament for the treatment of Hutchinson- Gilford progeria syndrome (HGPS).